Clopidogrel napadisilate

萘二磺酸氯吡格雷

Report date: 2023/01/10 17:56:57
First In Class

Base Information

Drug NameClopidogrel napadisilate
Drug Alias NameClopidogrel naphthalene-1,5- disulfonateClopidogrel napadisilate monohydratePidogle
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic P2 receptor antagonists
TargetsPurinergic P2 receptor
Therapy Area/IndicationsThrombosis
Global Approved IndicationsThrombosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2010/11/01
Country/TerritoryPortugalNetherlandsItaly +[5
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsThrombosis
Inactive IndicationsN/A

Other Information

ATC CodeB01AC04
Related LinksN/A